Hmdb loader
Survey
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusDetected but not Quantified
Creation Date2012-09-06 15:16:49 UTC
Update Date2022-03-07 02:51:35 UTC
HMDB IDHMDB0014332
Secondary Accession Numbers
  • HMDB14332
Metabolite Identification
Common NameLorazepam
DescriptionLorazepam is only found in individuals that have used or taken this drug. It is a benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent. [PubChem]Lorazepam binds to an allosteric site on GABA-A receptors, which are pentameric ionotropic receptors in the CNS. Binding potentiates the effects of the inhibitory neurotransmitter GABA, which upon binding opens the chloride channel in the receptor, allowing chloride influx and causing hyperpolerization of the neuron.
Structure
Data?1582753166
Synonyms
ValueSource
AtivanKegg
(+/-)-lorazepamHMDB
O-ChlorooxazepamHMDB
O-ChloroxazepamHMDB
AHP brand OF lorazepamMeSH, HMDB
apo LorazepamMeSH, HMDB
Llorens brand OF lorazepamMeSH, HMDB
Lorazepam ahp brandMeSH, HMDB
Lorazepam baxter brandMeSH, HMDB
Lorazepam medicalMeSH, HMDB
Lorazepam medix brandMeSH, HMDB
Lorazepam wyeth brandMeSH, HMDB
Lorazepam neuraxpharm brandMeSH, HMDB
Lorazepam ratiopharm brandMeSH, HMDB
Medix brand OF lorazepamMeSH, HMDB
novo LorazemMeSH, HMDB
novo-LorazemMeSH, HMDB
Novopharm brand OF lorazepamMeSH, HMDB
Lorazep von CTMeSH, HMDB
Neuraxpharm brand OF lorazepamMeSH, HMDB
Ratiopharm brand OF lorazepamMeSH, HMDB
Dolorgiet brand OF lorazepamMeSH, HMDB
DuralozamMeSH, HMDB
LaubeelMeSH, HMDB
Lorazepam apotex brandMeSH, HMDB
Lorazepam desitin brandMeSH, HMDB
Lorazepam CT-arzneimittel brandMeSH, HMDB
Lorazepam-ratiopharmMeSH, HMDB
Merck dura brand OF lorazepamMeSH, HMDB
Nu-lorazMeSH, HMDB
Riemser brand OF lorazepamMeSH, HMDB
Serra pamies brand OF lorazepamMeSH, HMDB
SinestronMeSH, HMDB
TemestaMeSH, HMDB
TolidMeSH, HMDB
Wyeth, orfidalMeSH, HMDB
CT Arzneimittel brand OF lorazepamMeSH, HMDB
ApoLorazepamMeSH, HMDB
Baxter brand OF lorazepamMeSH, HMDB
IdalpremMeSH, HMDB
Lorazepam dolorgiet brandMeSH, HMDB
Lorazepam medical brandMeSH, HMDB
Lorazepam novartis brandMeSH, HMDB
Lorazepam riemser brandMeSH, HMDB
Lorazepam ratiopharmMeSH, HMDB
Lorazepam-neuraxpharmMeSH, HMDB
Medical brand OF lorazepamMeSH, HMDB
Medical, lorazepamMeSH, HMDB
NovoLorazemMeSH, HMDB
Nu lorazMeSH, HMDB
Orfidal wyethMeSH, HMDB
SomagerolMeSH, HMDB
apo-LorazepamMeSH, HMDB
Apotex brand OF lorazepamMeSH, HMDB
Desitin brand OF lorazepamMeSH, HMDB
DonixMeSH, HMDB
DurazolamMeSH, HMDB
Lorazepam llorens brandMeSH, HMDB
Lorazepam novopharm brandMeSH, HMDB
Lorazepam nu-pharm brandMeSH, HMDB
Lorazepam neuraxpharmMeSH, HMDB
Novartis brand OF lorazepamMeSH, HMDB
Nu pharm brand OF lorazepamMeSH, HMDB
Nu-pharm brand OF lorazepamMeSH, HMDB
NuLorazMeSH, HMDB
SedicepanMeSH, HMDB
Wyeth brand OF lorazepamMeSH, HMDB
CT-Arzneimittel brand OF lorazepamMeSH, HMDB
Von CT, lorazepMeSH, HMDB
Chemical FormulaC15H10Cl2N2O2
Average Molecular Weight321.158
Monoisotopic Molecular Weight320.011932988
IUPAC Name7-chloro-5-(2-chlorophenyl)-3-hydroxy-2,3-dihydro-1H-1,4-benzodiazepin-2-one
Traditional Namelorazepam
CAS Registry Number846-49-1
SMILES
OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
InChI Identifier
InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)
InChI KeyDIWRORZWFLOCLC-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Alpha-amino acid or derivatives
  • Chlorobenzene
  • Halobenzene
  • Aryl chloride
  • Aryl halide
  • Monocyclic benzene moiety
  • Benzenoid
  • Carboxamide group
  • Ketimine
  • Secondary carboxylic acid amide
  • Lactam
  • Alkanolamine
  • Carboxylic acid derivative
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Imine
  • Organic oxygen compound
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Carbonyl group
  • Organic oxide
  • Organopnictogen compound
  • Organooxygen compound
  • Organohalogen compound
  • Organochloride
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Ontology
Not AvailableNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting Point166 - 168 °CNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.018 g/LNot Available
LogP3.5Not Available
Experimental Chromatographic Properties

Experimental Collision Cross Sections

Adduct TypeData SourceCCS Value (Å2)Reference
[M+H]+CBM165.830932474
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.018 g/LALOGPS
logP2.98ALOGPS
logP3.53ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)10.61ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area61.69 ŲChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.7 m³·mol⁻¹ChemAxon
Polarizability30.33 ųChemAxon
Number of Rings3ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+166.52730932474
DeepCCS[M-H]-164.16930932474
DeepCCS[M-2H]-197.05530932474
DeepCCS[M+Na]+172.6230932474
AllCCS[M+H]+168.332859911
AllCCS[M+H-H2O]+164.832859911
AllCCS[M+NH4]+171.632859911
AllCCS[M+Na]+172.532859911
AllCCS[M-H]-164.932859911
AllCCS[M+Na-2H]-164.232859911
AllCCS[M+HCOO]-163.432859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
LorazepamOC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C24211.0Standard polar33892256
LorazepamOC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C22435.5Standard non polar33892256
LorazepamOC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C22746.1Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Lorazepam,1TMS,isomer #1C[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2NC1=O2753.9Semi standard non polar33892256
Lorazepam,1TMS,isomer #2C[Si](C)(C)N1C(=O)C(O)N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C212571.4Semi standard non polar33892256
Lorazepam,2TMS,isomer #1C[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2N([Si](C)(C)C)C1=O2591.1Semi standard non polar33892256
Lorazepam,2TMS,isomer #1C[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2N([Si](C)(C)C)C1=O2612.5Standard non polar33892256
Lorazepam,2TMS,isomer #1C[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2N([Si](C)(C)C)C1=O3526.9Standard polar33892256
Lorazepam,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2NC1=O2909.3Semi standard non polar33892256
Lorazepam,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)N1C(=O)C(O)N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C212785.7Semi standard non polar33892256
Lorazepam,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2N([Si](C)(C)C(C)(C)C)C1=O2932.6Semi standard non polar33892256
Lorazepam,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2N([Si](C)(C)C(C)(C)C)C1=O3001.7Standard non polar33892256
Lorazepam,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC1N=C(C2=CC=CC=C2Cl)C2=CC(Cl)=CC=C2N([Si](C)(C)C(C)(C)C)C1=O3593.5Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental GC-MSGC-MS Spectrum - Lorazepam EI-B (Non-derivatized)splash10-009i-6791000000-942b7493f1e9fc3d12be2017-09-12HMDB team, MONA, MassBankView Spectrum
Experimental GC-MSGC-MS Spectrum - Lorazepam EI-B (Non-derivatized)splash10-009i-6791000000-942b7493f1e9fc3d12be2018-05-18HMDB team, MONA, MassBankView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Lorazepam GC-MS (Non-derivatized) - 70eV, Positivesplash10-004u-0290000000-b7b54d40e4a40249fc2d2017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Lorazepam GC-MS (1 TMS) - 70eV, Positivesplash10-00b9-9235000000-97d74a04d7ec48e6bb282017-10-06Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Lorazepam GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Lorazepam GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Lorazepam GC-MS (TMS_1_2) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Lorazepam GC-MS (TBDMS_1_1) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Lorazepam GC-MS (TBDMS_1_2) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
MSMass Spectrum (Electron Ionization)splash10-002r-4981000000-a567f7beb26ee18d061c2014-09-20Not AvailableView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-qTof , Positive-QTOFsplash10-00b9-0298000000-986499cda13643ef7d852017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOFsplash10-001i-0091000000-04730f82e569df7febdd2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOFsplash10-001i-0390000000-dd63d93f2fa81cbb59282017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOFsplash10-0udi-0930000000-3ecf1f2f10049a3cfee22017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOFsplash10-0udi-0910000000-95d23a9a121bf45ef8bf2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOFsplash10-0udi-0900000000-cdbe26e697f259770c282017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOFsplash10-0udi-0900000000-4046d54b4dd9bf7968be2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , negative-QTOFsplash10-001i-0091000000-abaf38ed3aa6e7d512452017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QTOF , positive-QTOFsplash10-052b-9000000000-dda683413448d04611232017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOFsplash10-00di-0009000000-53bbea620bd1e8b49eb32017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOFsplash10-0fb9-0095000000-793565a97e3afc2ce8582017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOFsplash10-004i-0090000000-41097b8a64363c5e2f942017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOFsplash10-004i-0290000000-a0694111a3943eca2b532017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOFsplash10-004i-0690000000-5a4728cb7e2473fc6b3c2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOFsplash10-01rf-0940000000-39d041fbab4fb67a5c412017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam , positive-QTOFsplash10-00b9-0298000000-986499cda13643ef7d852017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam LC-ESI-QFT , positive-QTOFsplash10-00b9-0196000000-2e53b39b27c66ec73fd22017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam 30V, Positive-QTOFsplash10-004i-0090000000-4b5b5c3dfb63873733bf2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Lorazepam -1V, Positive-QTOFsplash10-052b-9000000000-dda683413448d04611232021-09-20HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lorazepam 10V, Positive-QTOFsplash10-00di-0029000000-ee07ef7d365d458f9d342016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lorazepam 20V, Positive-QTOFsplash10-00di-0239000000-5c6908c1fea1275fb8742016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lorazepam 40V, Positive-QTOFsplash10-0zfr-1981000000-3701b2aca45eeea63d622016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lorazepam 10V, Negative-QTOFsplash10-014i-0009000000-58ac02858c22990ff3452016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lorazepam 20V, Negative-QTOFsplash10-014i-0339000000-f3e5eccf9c4e49dcfbcf2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Lorazepam 40V, Negative-QTOFsplash10-000i-3490000000-6b141b0755058109e70a2016-08-03Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Cytoplasm
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothNormal details
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00186 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00186 details
UrineDetected but not QuantifiedNot QuantifiedAdult (>18 years old)BothNormal details
Abnormal Concentrations
Not Available
Predicted Concentrations
BiospecimenValueOriginal ageOriginal sexOriginal conditionComments
Blood0.000 uMAdult (>18 years old)BothNormalPredicted based on drug qualities
Blood0.000 umol/mmol creatinineAdult (>18 years old)BothNormalPredicted based on drug qualities
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID3821
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem CompoundNot Available
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Heisterkamp DV, Cohen PJ: The effect of intravenous premedication with lorazepam (ativan), pentobarbitone or diazepam on recall. Br J Anaesth. 1975 Jan;47(1):79-81. [PubMed:238548 ]
  2. Milligan DW, Howard MR, Judd A: Premedication with lorazepam before bone marrow biopsy. J Clin Pathol. 1987 Jun;40(6):696-8. [PubMed:3611398 ]
  3. Lader M: Short-term versus long-term benzodiazepine therapy. Curr Med Res Opin. 1984;8 Suppl 4:120-6. [PubMed:6144459 ]
  4. Kemper N, Poser W, Poser S: [Benzodiazepine dependence: addiction potential of the benzodiazepines is greater than previously assumed (author's transl)]. Dtsch Med Wochenschr. 1980 Dec 5;105(49):1707-12. [PubMed:7439058 ]
  5. Maltais F, Laberge F, Laviolette M: A randomized, double-blind, placebo-controlled study of lorazepam as premedication for bronchoscopy. Chest. 1996 May;109(5):1195-8. [PubMed:8625666 ]
  6. (). FDA label . .

Only showing the first 10 proteins. There are 20 proteins in total.

Enzymes

General function:
Involved in ion transport
Specific function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular weight:
54161.8
References
  1. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
  2. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  3. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
General function:
Signal transduction mechanisms
Specific function:
Responsible for the manifestation of peripheral-type benzodiazepine recognition sites and is most likely to comprise binding domains for benzodiazepines and isoquinoline carboxamides. May play a role in the transport of porphyrins and heme. Plays a role in the transport of cholesterol across mitochondrial membranes in steroidogenic cells
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular weight:
18778.7
References
  1. Venneti S, Lopresti BJ, Wiley CA: The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. 2006 Dec;80(6):308-22. Epub 2006 Dec 6. [PubMed:17156911 ]
  2. Park CH, Carboni E, Wood PL, Gee KW: Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia. 1996 Jan;16(1):65-70. [PubMed:8787774 ]
  3. Uusi-Oukari M, Korpi ER: Specific alterations in the cerebellar GABA(A) receptors of an alcohol-sensitive ANT rat line. Alcohol Clin Exp Res. 1991 Mar;15(2):241-8. [PubMed:1647706 ]
  4. Miller EI, Wylie FM, Oliver JS: Detection of benzodiazepines in hair using ELISA and LC-ESI-MS-MS. J Anal Toxicol. 2006 Sep;30(7):441-8. [PubMed:16959136 ]
General function:
Involved in ion transport
Specific function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular weight:
51801.4
References
  1. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
  2. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  3. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
General function:
Involved in ion transport
Specific function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular weight:
51325.9
References
  1. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
  2. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  3. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
General function:
Involved in ion transport
Specific function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular weight:
55164.1
References
  1. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
  2. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  3. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
General function:
Involved in ion transport
Specific function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular weight:
61622.6
References
  1. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
  2. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  3. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
General function:
Involved in ion transport
Specific function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular weight:
52145.6
References
  1. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
  2. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  3. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
General function:
Involved in ion transport
Specific function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular weight:
51023.7
References
  1. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
  2. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  3. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
General function:
Involved in ion transport
Specific function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular weight:
54234.1
References
  1. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
  2. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  3. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
General function:
Involved in ion transport
Specific function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular weight:
59149.9
References
  1. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
  2. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  3. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]

Only showing the first 10 proteins. There are 20 proteins in total.